HIV peptide vaults and methods of making and using thereof
Disclosed herein are compositions comprising HIV peptide vaults, which are vault particles comprising complexes of MVP proteins and one or more HIV peptides bound or genetically linked to one or more MVP proteins or packaged within the internal cavities of the vault particles and methods of using thereof.
1. An HIV peptide vault which comprises a vault particle comprising a complex of MVP proteins and at least one HIV peptide bound or genetically linked to at least one MVP protein or packaged within an internal cavity of the vault particle, wherein the at least one HIV peptide comprises a sequence having at least 96% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16.
2. An HIV peptide vault which comprises a vault particle comprising a complex of MVP proteins and at least one HIV peptide bound or genetically linked to the N-terminus of at least one MVP protein, wherein the at least one HIV peptide comprises a sequence having at least 96% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16.
3. The HIV peptide vault according to claim 1 , wherein the HIV peptide consists of a sequence having at least at least 96% sequence identity to a sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16.
4. The HIV peptide vault according to claim 1 , wherein the HIV peptide consists of a sequence having SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16.
5. The HIV peptide vault according to claim 1 , wherein the HIV peptide is bound to the N-terminus of the at least one MVP protein.
6. The HIV peptide vault according to claim 1 , wherein the HIV peptide is genetically linked to the at least one MVP protein or to a mINT domain.
7. The HIV peptide vault according to claim 1 , wherein the HIV peptide is genetically linked to the N-terminus of the at least one MVP protein.
8. The HIV peptide vault according to claim 7 , wherein the HIV peptide is genetically linked to the at least one MVP protein via a flexible linker.
9. A composition comprising at least one HIV peptide vault according to claim 1 .
10. The composition according to claim 9 , wherein the at least one HIV peptide vault is present in an immunogenic amount.
11. The composition according to claim 9 , and further comprising a pharmaceutically acceptable carrier.
12. A vaccine comprising at least one HIV peptide vault according to claim 1 .
13. The vaccine according to claim 12 , and further comprising an adjuvant.
14. A method of inducing an immune response in a subject, which comprises administering an immunogenic amount of the HIV peptide vault according to claim 1 .